Associate Professor Daniele Pastori

Associate Professor Daniele Pastori

Sapienza University of Rome, Rome (Italy)

Member of:

Daniele Pastori is a MD and Associate Professor of Internal and Emergency Medicine at Sapienza University of Rome, Italy. He has been working on thrombosis and anticoagulant therapy since 2014. He co-authored >200 publications on clinical and translational research on cardiovascular and thrombotic diseases such as atrial fibrillation, antiphospholipid syndrome, heart valves, ischemic heart disease and venous thromboembolism.

Presentations Articles

A systematic review and meta-analysis on the predictive value of the C2HEST score to predict new onset atrial fibrillation in >11 million Western and Asian subjects.

Event: ESC Congress 2024

Topic: Scores

Session: Risk score for risk prediction in cardiovascular disease

Access

Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry.

Event: ESC Congress 2023

Topic: Drug therapy

Session: Risk factors and prevention: lipids (1)

Access

Bleeding and thrombotic events in patients with atrial fibrillation and cancer: a systematic review and meta-regression analysis.

Event: ESC Congress 2022

Topic: Clinical

Session: Clinical scenarios in atrial fibrillation

Access

Bleeding risk prediction in a large cohort of patients with atrial fibrillation and cancer: A nationwide cohort study

Event: ESC Congress 2022

Topic: Oral Anticoagulation

Session: Oral anticoagulation in real life

Access

C: Cardiovascular risk factor and comorbidity optimisation (including lifestyle changes).

Event: ESC Heart & Stroke 2022

Topic: Stroke

Session: Integrated care management for optimizing heart disease and stroke

Access

Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer.

Event: ESC Congress 2021 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Atrial fibrillation e-posters

Access

Prevalence of heart failure with preserved ejection fraction in antiphospholipid antibodies syndrome. The multicenter ATHERO-APS study.

Event: ESC Congress 2021 - The Digital Experience

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic heart failure e-posters

Access

Risks of thromboembolism, mortality and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study.

Event: EHRA 2021

Topic: Clinical

Session: Outcome of atrial fibrillation

Access

Comparison of bleeding risk scores in patients with atrial fibrillation and cancer.

Event: EHRA 2021

Topic: Clinical

Session: Outcome of atrial fibrillation

Access

Performance of the C2HEST score to predict sustained atrial high-rate episodes in patients implanted with cardiac implantable electronic device

Event: EHRA 2021

Topic: Clinical

Session: News about electrophysiology in general

Access

ESC 365 is supported by

Explore sponsored resources

Associate Professor Daniele Pastori

Biography

Contributor content

A systematic review and meta-analysis on the predictive value of the C2HEST score to predict new onset atrial fibrillation in >11 million Western and Asian subjects.

Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry.

Bleeding and thrombotic events in patients with atrial fibrillation and cancer: a systematic review and meta-regression analysis.

Bleeding risk prediction in a large cohort of patients with atrial fibrillation and cancer: A nationwide cohort study

C: Cardiovascular risk factor and comorbidity optimisation (including lifestyle changes).

Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer.

Prevalence of heart failure with preserved ejection fraction in antiphospholipid antibodies syndrome. The multicenter ATHERO-APS study.

Risks of thromboembolism, mortality and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study.

Comparison of bleeding risk scores in patients with atrial fibrillation and cancer.

Performance of the C2HEST score to predict sustained atrial high-rate episodes in patients implanted with cardiac implantable electronic device

ESC 365 is supported by

Associate Professor Daniele Pastori Follow

Biography

Contributor content

A systematic review and meta-analysis on the predictive value of the C2HEST score to predict new onset atrial fibrillation in >11 million Western and Asian subjects.

Statins under-treatment and mortality in patients with atrial fibrillation. Insights from the nationwide START registry.

Bleeding and thrombotic events in patients with atrial fibrillation and cancer: a systematic review and meta-regression analysis.

Bleeding risk prediction in a large cohort of patients with atrial fibrillation and cancer: A nationwide cohort study

C: Cardiovascular risk factor and comorbidity optimisation (including lifestyle changes).

Comparison of the HAS-BLED, ORBIT and ATRIA bleeding risk scores in 399,344 patients with atrial fibrillation and cancer.

Prevalence of heart failure with preserved ejection fraction in antiphospholipid antibodies syndrome. The multicenter ATHERO-APS study.

Risks of thromboembolism, mortality and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study.

Comparison of bleeding risk scores in patients with atrial fibrillation and cancer.

Performance of the C2HEST score to predict sustained atrial high-rate episodes in patients implanted with cardiac implantable electronic device

ESC 365 is supported by

Associate Professor Daniele Pastori